• Behavioral Health
  • Clinical Insights
  • Treatment

March 2024 drug trend report

Mar 13th, 2024

Staying on top of new drug launches and shortages can be difficult. Read Genoa Healthcare’s latest drug trend report for an overview and connect with your local pharmacy team to learn more.

Brand name drug launches*

Uzedy

  • Indicated for: Treatment of schizophrenia in adults
  • Dosage form: Long-acting injectable administered subcutaneously in the abdomen or upper arm.
  • Status: Available now

For more information on the new treatment option for adults living with schizophrenia, read the Uzedy™ blog post here.

Generic drug launches*

Pradaxa (dabigatran etexilate mesylate)

  • Indicated for: Treatment of nonvalvular partial fibrillation and venous thromboembolism
  • Dosage form: Capsules
  • Status: Available now

Top drug shortages*

Naltrexone

  • Indicated for: Treatment of alcohol and/or opioid use disorder
  • Status: Recovery TBD

Trulicity

  • Indicated for: Treatment of type 2 diabetes
  • Status: Recovery TBD

Paliperidone

  • Indicated for: Treatment of schizophrenia and schizoaffective disorder
  • Status: Recovery TBD

*Information on this page was accurate at the time of posting. Shortage recovery dates are only estimates. These estimates are based on the distribution information that Genoa has access to.

Recent Posts


  • Behavioral Health
  • Clinical Insights
  • Treatment
Why medication-assisted treatment is essential for improving patient outcomes

1. Methadone and buprenorphine reduce risk of death after opioid overdose. (2018, June 19). NIH. 2. Methadone and buprenorphine reduce risk of death after opioid overdose. (2018, June 19). NIH....

  • 340B
Your questions, answered: 340B manufacturer pricing restrictions

Drug manufacturers began implementing restrictions for 340B pricing in 2020, citing alleged misuse by safety-net providers and explosive growth of the 340B Drug Pricing Program. Since then, restrictions for the...

  • Behavioral Health
  • Clinical Insights
  • Treatment
Currently available and emerging therapy options for treatment-resistant depression

Studies show that 50% of people with major depressive disorder don’t respond adequately to initial antidepressant treatment.1 Additionally, an estimated 30% of people with major depressive disorder (MDD) experience treatment-resistant...

  • Art Celebration
  • Consumer Stories
  • People-first Pharmacy Care
Genoa Art Celebration participant heals through art, helps others after losing daughter to substance use disorder

Content warning: This post discusses mental illness and substance use. Please call the Suicide and Crisis Lifeline at 988, the Substance Abuse and Mental Health Services Administration’s National Helpline at...